NDP antibodies are polyclonal or monoclonal reagents developed to bind epitopes on the norrin protein. Key characteristics include:
Epitope Specificity: Antibodies target regions spanning the full-length protein (Abcam ), N-terminal domains (Boster ), or central regions (Bio-Techne ).
Applications: Primarily used in Western blot (WB), immunocytochemistry (ICC), and immunohistochemistry (IHC) to analyze norrin expression in tissues .
Sensitivity: Western blot detection limits vary; R&D Systems’ AF3014 antibody detects human norrin in lysates .
NDP antibodies are pivotal in studying norrin’s role in developmental biology and disease.
In a landmark study, AAV9-mediated NDP gene therapy restored retinal and cochlear function in Ndp-KO mice . Antibodies were used to:
Confirm Transgene Expression: qRT-PCR and WB detected human NDP mRNA and EGFP-P2A-NDP fusion protein in treated retinas and cochleae .
Assess Therapeutic Efficacy: Neonatal treatment preserved retinal vascularization and auditory function, while juvenile/adult treatment partially rescued cochlear pathology .
Norrin activates β-catenin signaling via FZD4/LRP5 receptors . Antibodies enable:
TopFlash Reporter Assays: Confirming recombinant norrin’s ability to activate canonical Wnt pathways .
Surrogate Antibody Studies: A FZD4:LRP5 agonist antibody (F4L5.13) mimics norrin’s effects on endothelial barrier function, highlighting cross-talk between Wnt-independent and -dependent pathways .
NDP antibodies may aid in:
Norrie Disease Diagnosis: Detecting norrin protein levels in patient samples to confirm NDP mutations .
Monitoring Gene Therapy: Tracking transgene expression post-treatment in clinical trials .
Endpoint | Neonatal (P2) | Juvenile (P21) | Young Adult (P30) |
---|---|---|---|
Retinal Vascularization | Fully restored | Partial recovery | Limited improvement |
Cochlear Hair Cells | Complete preservation | Partial survival | Reduced progression |
Hearing Function | Normalized ABR | Improved thresholds | Stabilized loss |